Table 1.
Comparison of the serum MIC-1 levels before treatment among early-stage NSCLC patients with different clinical and pathological characteristics
| Characteristics | n | Serum levels of MIC-1 (pg/ml), mean ± SD | t | P |
|---|---|---|---|---|
| Age | 1.052 | 0.001 | ||
| <60 years | 64 | 1221 ± 838 | ||
| ≥60 years | 88 | 1666 ± 810 | ||
| Gender | 0.303 | 0.030 | ||
| Female | 89 | 1604 ± 708 | ||
| Male | 63 | 1302 ± 725 | ||
| Tumor size | 0.352 | 0.200 | ||
| <3 cm | 105 | 1427 ± 887 | ||
| ≥3 cm | 47 | 1595 ± 749 | ||
| Smoking history | 0.384 | 0.060 | ||
| <20 years | 83 | 1361 ± 926 | ||
| ≥20 years | 69 | 1620 ± 726 | ||
| Histological type | 1.332 | 0.458 | ||
| Squamous cell | 36 | 1579 ± 730 | ||
| Adenocarcinoma | 116 | 1447 ± 910 | ||
| Stage | 2.420 | 0.141 | ||
| I | 98 | 1035 ± 814 | ||
| II | 54 | 1615 ± 898 | ||
| Differentiation | 0.352 | 0.184 | ||
| Moderate-well | 38 | 1320 ± 1057 | ||
| Poor | 114 | 1532 ± 764 | ||
| T stage | 4.008 | 0.066 | ||
| T1 | 42 | 1224 ± 648 | ||
| T2 | 101 | 1586 ± 924 | ||
| T3 | 9 | 1466 ± 512 | ||
| N stage | 0.252 | 0.193 | ||
| N0 | 124 | 1430 ± 798 | ||
| N1 | 24 | 1675 ± 1461 | ||
| N2 | 4 | 1881 ± 1600 | ||
| Recurrence/metastasis | 0.003 | 0.270 | ||
| No | 118 | 1438 ± 866 | ||
| Yes | 34 | 1618 ± 779 | ||
| Survival | 0.008 | 0.042 | ||
| Yes | 134 | 1428 ± 852 | ||
| No | 18 | 1859 ± 737 |
MIC-1: Macrophage inhibitory cytokine-1; NSCLC: Nonsmall cell lung cancer; SD: Standard deviation.